Status:
COMPLETED
Safety and Immunogenicity of Oxford AstraZeneca Vaccine Against COVID-19 Infection
Lead Sponsor:
Zagazig University
Conditions:
Vaccine Adverse Reaction
Seroconversion
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
After SARS-COV-2 inactivated vaccine authorization for use in different countries including Egypt, investigating its immunogenicity, safety, and efficacy in preventing COVID-19 infection is highly nee...
Detailed Description
This study will be conducted at Zagazig University hospital. Laboratory work will be implemented at Immunology Research Laboratory at Microbiology and Immunology Department, Faculty of Medicine, Zagaz...
Eligibility Criteria
Inclusion
- Healthy healthcare workers
Exclusion
- Healthy healthcare workers' refusal.
- Pregnancy and lactation.
- Confirmed acute cases of SARS-CoV-2 Infection
- Having a history of SARS-CoV-2 infection in the past 3 months.
- Fever (body temperature \> 37.0 ℃), dry cough, fatigue, nasal obstruction, runny nose, pharyngeal pain, myalgia, diarrhea, shortness of breath and dyspnea occurred within 14 days before vaccination.
- History of allergy to any vaccines
- Previous vaccination within the last 30 days
Key Trial Info
Start Date :
February 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2021
Estimated Enrollment :
246 Patients enrolled
Trial Details
Trial ID
NCT04756271
Start Date
February 11 2021
End Date
December 22 2021
Last Update
February 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University Faculty of Medicine
Zagazig, Sharqia Province, Egypt, 44519